Moleculin Biotech (MBRX) Competitors $0.87 -0.04 (-4.80%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.88 +0.00 (+0.01%) As of 04/17/2025 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBRX vs. PDSB, ACRV, SKYE, TNYA, IMMX, OKUR, ANEB, AADI, RPTX, and CUEShould you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include PDS Biotechnology (PDSB), Acrivon Therapeutics (ACRV), Skye Bioscience (SKYE), Tenaya Therapeutics (TNYA), Immix Biopharma (IMMX), OnKure Therapeutics (OKUR), Anebulo Pharmaceuticals (ANEB), Aadi Bioscience (AADI), Repare Therapeutics (RPTX), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry. Moleculin Biotech vs. PDS Biotechnology Acrivon Therapeutics Skye Bioscience Tenaya Therapeutics Immix Biopharma OnKure Therapeutics Anebulo Pharmaceuticals Aadi Bioscience Repare Therapeutics Cue Biopharma Moleculin Biotech (NASDAQ:MBRX) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, community ranking, analyst recommendations, media sentiment, profitability, institutional ownership and risk. Do analysts rate MBRX or PDSB? Moleculin Biotech presently has a consensus price target of $6.00, suggesting a potential upside of 585.79%. PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 733.33%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than Moleculin Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has more volatility and risk, MBRX or PDSB? Moleculin Biotech has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Do institutionals and insiders hold more shares of MBRX or PDSB? 15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 1.9% of Moleculin Biotech shares are owned by insiders. Comparatively, 9.5% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community prefer MBRX or PDSB? Moleculin Biotech received 156 more outperform votes than PDS Biotechnology when rated by MarketBeat users. However, 70.75% of users gave PDS Biotechnology an outperform vote while only 49.36% of users gave Moleculin Biotech an outperform vote. CompanyUnderperformOutperformMoleculin BiotechOutperform Votes23149.36% Underperform Votes23750.64% PDS BiotechnologyOutperform Votes7570.75% Underperform Votes3129.25% Is MBRX or PDSB more profitable? PDS Biotechnology's return on equity of -139.57% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Moleculin BiotechN/A -157.44% -97.16% PDS Biotechnology N/A -139.57%-67.22% Does the media prefer MBRX or PDSB? In the previous week, Moleculin Biotech and Moleculin Biotech both had 2 articles in the media. PDS Biotechnology's average media sentiment score of 0.40 beat Moleculin Biotech's score of -0.50 indicating that PDS Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, MBRX or PDSB? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoleculin BiotechN/AN/A-$29.77MN/AN/APDS BiotechnologyN/AN/A-$42.94M-$1.03-1.05 SummaryPDS Biotechnology beats Moleculin Biotech on 10 of the 13 factors compared between the two stocks. Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBRX vs. The Competition Export to ExcelMetricMoleculin BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.25M$6.45B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.30%P/E RatioN/A6.8921.8017.80Price / SalesN/A231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book0.075.936.443.98Net Income-$29.77M$142.99M$3.21B$247.73M7 Day Performance9.39%4.42%2.87%1.81%1 Month Performance-19.73%-12.73%-8.63%-6.98%1 Year Performance-80.73%-9.48%11.46%1.37% Moleculin Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBRXMoleculin Biotech1.9552 of 5 stars$0.87-4.8%$6.00+585.8%-79.6%$12.25MN/A0.0020Short Interest ↑Gap DownPDSBPDS Biotechnology1.5401 of 5 stars$0.96+1.4%$9.00+834.4%-60.3%$43.73MN/A-0.8320Short Interest ↓ACRVAcrivon Therapeutics1.737 of 5 stars$1.39-7.9%$23.17+1,566.7%-82.5%$43.58MN/A-0.5158Short Interest ↑Gap DownSKYESkye Bioscience1.1913 of 5 stars$1.39+6.9%$18.00+1,195.0%-91.7%$43.06MN/A-1.9311Analyst RevisionTNYATenaya Therapeutics3.0535 of 5 stars$0.48-3.7%$6.25+1,201.8%-89.5%$42.05MN/A-0.33110Gap UpHigh Trading VolumeIMMXImmix Biopharma2.2661 of 5 stars$1.51+0.7%$7.00+363.6%-33.6%$41.86MN/A-1.789OKUROnKure Therapeutics2.4888 of 5 stars$3.09-1.3%$32.33+946.4%N/A$41.52MN/A-0.25N/AGap DownHigh Trading VolumeANEBAnebulo Pharmaceuticals2.7933 of 5 stars$1.01-1.0%$8.00+692.1%-66.3%$41.50MN/A-3.614Short Interest ↓Positive NewsGap UpAADIAadi Bioscience0.9262 of 5 stars$1.66+1.2%$1.67+0.4%-15.4%$41.00M$25.07M-0.7340Gap DownRPTXRepare Therapeutics3.1164 of 5 stars$0.96-4.0%$4.50+368.9%-62.6%$40.80M$53.48M-0.48180Short Interest ↓Gap DownCUECue Biopharma4.3203 of 5 stars$0.63-7.3%$4.75+659.0%-53.3%$39.64M$9.53M-0.7060 Related Companies and Tools Related Companies PDSB Competitors ACRV Competitors SKYE Competitors TNYA Competitors IMMX Competitors OKUR Competitors ANEB Competitors AADI Competitors RPTX Competitors CUE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBRX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MBRX Stock Free MBRX Stock Alerts